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Background: A nef gene is present in all primate lentiviral genomes and is important for high viral loads and
progression to AIDS in human or experimental macaque hosts of HIV or SIV, respectively. In these hosts, infection of
the thymus results in a decreased output of naive T cells that may contribute to the development of
immunodeficiency. We have previously shown that HIV-1 subtype B Nef proteins can block human T-cell develop-
ment. However, the underlying mechanism(s) and the conservation of this Nef function between different groups
of HIV and SIV remained to be determined.
Results: We investigated whether reduction of thymic output is a conserved function of highly divergent lentiviral
Nef proteins including those from both types of human immunodeficiency viruses (HIV-1 and HIV-2), their direct
simian counterparts (SIVcpz, SIVgor and SIVsmm, respectively), and some additional SIV strains. We found that ex-
pression of most of these nef alleles in thymocyte progenitors impaired T-cell development and reduced thymic
output. For HIV-1 Nef, binding to active p21 protein (Cdc42/Rac)-activated kinase (PAK2) was a major determinant
of this function. In contrast, selective disruption of PAK2 binding did not eliminate the effect on T-cell development
of SIVmac239 Nef, as was shown by expressing mutants in a newly discovered PAK2 activating structural motif
(PASM) constituted by residues I117, H121, T218 and Y221, as well as previously described mutants. Rather, down-
modulation of cell surface CD3 was sufficient for reduced thymic output by SIVmac Nef, while other functions of
SIV Nefs contributed.
Conclusions: Our results indicate that primate lentiviral Nef proteins impair development of thymocyte precursors
into T cells in multiple ways. The interaction of HIV-1 Nef with active PAK2 by HIV-1 seem to be most detrimental,
and downregulation of CD3 by HIV-2 and most SIV Nef proteins sufficient for reduced thymic output. Since the
reduction of thymic output by Nef is a conserved property of divergent lentiviruses, it is likely to be relevant for
peripheral T-cell depletion in poorly adapted primate lentiviral infections.
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Humans infected with HIV develop AIDS due to a
progressive decline in their lymphocyte numbers and
function. An imbalance between production and de-
struction of peripheral CD4+ T cells leads to their pro-
gressive decline over time and eventually to AIDS [1,2].
The thymus is susceptible to HIV-1 infection, which* Correspondence: Bruno.Verhasselt@UGent.be
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reproduction in any medium, provided the orcompromises thymic function and results in decreased
thymic output [3,4]. Also rhesus macaques experimen-
tally infected with SIV show thymic atrophy and reduced
thymic output [5-7].
The accessory viral protein Nef plays a key role in effi-
cient viral replication in vivo and greatly accelerates dis-
ease progression in poorly adapted hosts of primate
lentiviruses. Initially, it was shown that an intact nef
gene is essential for the maintenance of high viral load
and disease progression in macaques [8]. Subsequently,
defective nef genes were detected in several long-termtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Natural Nef variants used
CD3 CD4 CXCR4 MHC-I PAK2 TGR References
HIV-1 - + +/− + +
B2 - * + +/− + ND 0.4 * [29]
B10 - * + +/− + ND 0.4 * [29]
B2681 - * + +/− + ND 0.6 * [29]
BA-L - + +/− + ND 0.6 * [29]
NA7 - + +/− + +/− 0.4 [25,29,31]
SF2 - + +/− + + 0.1 * [29,31]
C794 - * + +/− - ND 0.6 * [29]
C1044 - * + +/− - ND 0.2 * [29]
C1422 - * + +/− + ND 0.2 * [29]
O4 - * + +/− + ND 0.1 * [29]
O8 - * + - - ND 1.6 * [29]
O14 - * + +/− + ND 0.2 * [29]
HIV-2 ++ + + +
EHO ++* +* +* +* ND 0.1 * [32]
171 + * + - +/− ND 0.6 * [29]
SIV + ++ +
cpz - + + + + 1.0 * [28,31]
gor - + ++ + ND 0.3 * [33]
mac ++ + ++ + + 0.1 * [28,31,34]
blu ++ + + + +/− 0.2 * [28,31]
smm ++ + ++ + + 0.3 * [28,31,34]
Table shows properties of the Nef proteins (grouped according to origin) used
in this study, with reference to published data wherever possible: *indicates
this study is the first report. Downregulation of cell surface markers by Nef in
transduced PBLs as indicated in column heading is reported semi-quantitati-
vely: from – (no downregulation), over +/− and + to ++ (strong downregula-
tion). PAK2: binding to PAK2 semi-quantitatively: from – (no detectable
binding), over +/− to + (strong binding similar to corresponding wild-type).
In boldface the expected phenotype for Nef from HIV-1, HIV-2 and SIV origin,
when stereotypical. TGR: thymocyte generation ratio, average value is shown,
control value is typically about 1.4.
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viral loads [9,10]. Moreover, Nef expression alone was
sufficient to induce an AIDS-like disease in mice
[11-13]. Nef performs multiple activities, such as modu-
lation of cell surface receptors (e.g. CD4, CD8β, CD28,
MHC-I and CXCR4), alteration of signal transduction
pathways, reducing cellular motility by binding active
p21 protein (Cdc42/Rac)-activated kinase (PAK2), and
enhancement of viral infectivity and replication [14-18].
HIV-2, SIVsmm, SIVmac and most other SIV Nef pro-
teins are more potent in CXCR4 and CD28 downregula-
tion than HIV-1 Nefs, and in addition capable of
downregulating CD3 cell surface expression [19-23].
Previous studies have shown that Nef alleles derived
from several HIV-1 group M subtype B strains (e.g.
NL4-3, NA7 and LAI) were able to impair T-cell devel-
opment from CD34+ hematopoietic progenitor cells
[24-26]. In HIV-1 (LAI) infected bone marrow-liver-
thymus humanized (BLT) mice Nef was essential for
thymocyte depletion [27]. However, a thorough under-
standing of the underlying molecular mechanism is lack-
ing and it is unclear whether Nef proteins from other
subtypes or groups of HIV-1, HIV-2 and SIV also reduce
thymic output.
Therefore, we analyzed a panel of Nef proteins from
HIV-1 group M, group O and HIV-2, their simian pre-
cursors SIVcpz, SIVgor and SIVsmm, respectively, and
SIVmac and SIVblu for their ability to interfere with the
development of human thymocytes in fetal thymic organ
cultures (FTOC). We show that reduced thymic output
is conserved between these HIV and SIV Nef proteins.
Domains and residues important for PAK2 binding, such
as the C-terminal phenylalanine, were important for re-
duced thymic output by HIV-1 Nefs that are generally
unable to down-modulate CD3 and only weakly affect
CXCR4 expression. In comparison, SIVmac Nef mutants
that did not bind PAK2 were still able to reduce thymic
output because downregulation of CD3 proved to be
sufficient for this effect. Finally, mutations in the SIVblu
Nef that disrupted both PAK2 interaction and CD3 but
not CXCR4 down-modulation did not fully eliminate its
effect on thymic output, suggesting that reduced CXCR4
signaling is contributing the effect of SIV Nefs. Our re-
sults indicate that reduction of thymic output is a con-
served property of primate lentiviral Nef proteins and
mediated by effects on multiple cellular factors that are
involved in T-cell signaling and migration.
Results
Reduction of thymic output is a conserved property of
primate lentiviral Nefs
We previously reported that expression of Nefs from
HIV-1 subtype B strains (NL4.3, NA7 and LAI) in
thymic progenitors impaired the development of T cells[24,25]. To assess whether this function is conserved in
other primate lentiviral Nef proteins, we analyzed a
panel of previously described HIV-1 group M (subtype B
and C), HIV-1 group O, HIV-2, SIVcpz, SIVgor, SIVmac,
SIVblu and SIVsmm nef alleles [28,29] (overview in
Table 1). Human thymic CD34+ T-cell progenitor cells
were transduced with a retroviral vector, co-expressing
Nef and the enhanced green fluorescent protein (eGFP)
marker from a single bicistronic mRNA, and assayed
in vitro in FTOC. After 21 days of FTOC culture,
CD34+ cells transduced with the control vector express-
ing eGFP, developed into double positive (CD4+CD8+),
CD4+CD8- and a few CD4-CD8+ single positive cells
with similar levels of surface marker expression (CD4,
CD8β, CD3) compared to that of non-transduced eGFP-
cells (Figure 1A, B), as reported before [24,25]. In com-
parison, HIV-1 Nef expressing cells showed reduced
CD4 and CD8β expression. As reported before [24,25],
Figure 1 Reduction of thymic output is a conserved property of primate lentiviral Nef proteins. Flow cytometric analysis of FTOC initiated
with transduced CD34+ thymic progenitors. (A) Gating strategy: R1 and R2 to gate on living cells of human origin (not staining with anti-mouse
CD45 Cy-Chrome). For indicated plots in panel (B) eGFP- and eGFP+ cells were gated using the histogram gates shown (R3 and R4). (B) Dot plots
show control eGFP (left) or Nef NA7-IRES-eGFP transduced cultures (right) stained as indicated gated on eGFP- cells (upper plots) and eGFP+ cells
(middle plots); and eGFP vs. CD4 or CD3 gated on live human cells (lower plots). Quadrants were set to include 99% of non-transduced cells
stained with isotypic controls in lower left quadrant. Numbers in plots indicate mean fluorescent intensity (MFI): for upper and middle plots of
the marker on the adjacent axis for the total population (all quadrants), for the lower plots MFI’s for the marker on the Y-axis for all eGFP- cells
(upper and lower left quadrants) or all eGFP+ cells (upper and lower right quadrants) are indicated. (C) Representative examples of eGFP vs. CD4
and eGFP vs. CD3 stainings, gated on live human cells of Nef transduced cultures, as indicated. Quadrants and numbers in plots as in lower plots
panel B, if sufficient events available. (D) T-cell generation ratio (TGR) calculated from Nef transduced cultures, as indicated. Bars represent aver-
ages of at least 3 independent experiments, error bars indicate standard deviation. Nef proteins that do not downregulate CD3 are shown in dark
grey (in red functional defective mutant HIV-1 O8), those that do in light grey (in blue functional mutant HIV-2 171). Difference compared to con-
trol eGFP (white bar) was tested with Kruskal-Wallis with Dunn’s correction for multiple testing, *p < 0.05, **p < 0.005.
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skewed to higher levels of cell surface CD3 expression
compared to eGFP- cells from the same culture
(Figure 1B). Since transduced and non-transduced pro-
genitors are not separated before FTOC, the non-
transduced thymocytes generated serve as an internal
control for the transduced population. Nearly all of the
Nef proteins tested reduced thymic output, some to such
an extent that hardly any eGFP+ and thus Nef expressing
cells could be detected (representative dot plots shown
in Figure 1C). To measure Nef induced thymic deple-
tion, we calculated the thymocyte generation ratio(TGR) defined as the ratio of the percentage of eGFP+
thymocytes harvested to the percentage of eGFP+ pro-
genitors put in FTOC (Figure 1D). This TGR parameter
was shown before to be a robust measure of T-cell gen-
eration potency from transduced progenitors [25]. All
HIV-1 group M subtype B and C, as well as two out of
three group O Nef proteins showed a pronounced effect
on thymopoiesis (Figure 1D). This was due to a develop-
mental defect and not due to toxicity, as Nef expressing
thymocytes grown in suspension culture showed com-
parable survival to control eGFP transduced cells ([24]
and data not shown). Remarkably, the natural mutant
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development. Of note, this allele is mutated in the
valine-glycine-phenylalanine (VGF) domain which is
critical for many Nef functions (MHC-I and CXCR4
downregulation, PAK2 binding and cofilin hyperpho-
sphorylation, inhibition of T-cell receptor (TCR)
triggering-induced actin ring formation, targeting Lck to
the trans-Golgi network and enhancement of infectivity
and replication, but not for CD4 downregulation)
[29,30]. For HIV-2, EHO Nef reduced T-cell generation
(TGR 0.1) much more potently than 171 Nef (TGR 0.6)
in comparison to control eGFP transduced cultures
(TGR 1.4) (Figure 1D and Table 1). The latter protein
was shown to be defective for CXCR4 downregulation,
and reduced in its ability to downregulate MHC-I [29]
and CD3 (Table 1). All of the SIV Nef proteins tested
reduced T-cell generation, albeit with different potency.
SIVcpz was the least potent, while SIVmac blocked T-
cell development almost completely. To accomplish this,
the SIV derived Nefs apparently can interact with the
relevant human proteins in the developing thymocytes.
Overall, these results demonstrate that the capacity to
reduction of thymic output is a conserved feature of
highly divergent lentiviral Nef proteins.Table 2 Artificial Nef mutants used
CD3 CD4 CXCR4
HIV-1 - + +/−
B2 VGF-AAA - * + * - *
NA7 VGF-AAA - * + -
C1422 VGF-AAA - * + * - *
NA7 F191H - + - *
NA7 F191R - + - *
SF2 F195I - * + - *
SF2 F195A - * + - *
SIV + ++
mac AXXP ++ * + +/− *
mac AXXA ++ + - *
mac PXXA ++ * + - *
mac H121R ++ * + * - *
mac Y221R ++ * + * - *
mac H121R/Y221R ++ * + * - *
mac Δ153 ++ - - *
mac Δ183 - - - *
blu RR-AA - + * + *
Table shows properties of the mutated Nef proteins (grouped according to origin) u
*indicates this study is the first report. Downregulation of cell surface markers by N
semi-quantitatively: from – (no downregulation), over +/− and + to ++ (strong down
binding), over +/− to + (strong binding similar to corresponding wild-type). In boldf
stereotypical. TGR: thymocyte generation ratio, control value is typically about 1.4. NDisturbance of T-cell development by HIV-1 Nef requires
an intact VGF motif and is affected by PAK2 binding
The Nef protein of the O8 strain is deleted in the VGF
domain and in the first proline of the neighboring poly-
proline domain (PxxP). Although the importance of the
latter domain for deregulation of T-cell development
was shown before [25], the functional relevance of the
VGF motif in this respect is unknown. To investigate
the relevance of this VGF domain for reduced thymic
output by Nef alleles from various group M HIV-1
strains, we mutated the VGF motif to an alanine triplet
(VGF-AAA) in subtype B (NA7 and B2), and subtype C
(C1422) Nefs as described before [29]. Table 2 shows an
overview of all mutants used in this study, their ability
to downregulate the cell surface markers assessed in pri-
mary CD4+ T cells (PBLs iso primary CD4+ T cells), to
bind PAK2 and their effect on thymic output as mea-
sured by TGRs. When the VGF mutants were expressed
in thymocytes, cell surface CD4 and CD3 levels were
similar to that of thymocytes expressing wild-type Nefs
(Figure 2A). However, the number of thymocytes gener-
ated was significantly increased (Figure 2B). This is in
line with our previous observations, indicating that do-
mains important in the signaling properties of Nef, suchMHC-I PAK2 TGR Reference
+
- * ND 2.5 * This study
- - 3.7 * [29]
- * ND 1.7 * This study
+ +/− 1.0 * [35]
+ - 1.7 * [35]
+ +/− 0.3 * [36]
+ - 0.7 * [37]
+
+ + * 0.3 * [38]
+ +/− * 0.2 * [38,39]
+ +/− * 0.2 * [38]
- * +/− * 0.3 * This study
- * +/− * 0.6 * This study
- * - * 0.5 * This study
- - * 0.2 * [39]
- - * 1.2 * [39]
+/−* - * 0.5 * [40]
sed in this study, with reference to published data wherever possible:
ef in transduced CD4+ PBLs as indicated in column heading is reported
regulation). PAK2: binding to PAK2 semi-quantitatively: from – (no detectable
ace the expected phenotype for Nef from HIV-1, HIV-2 and SIV origin, when
D: not determined.
Figure 2 Reduction of thymic output by HIV-1 Nef requires an intact VGF motif. Flow cytometric analysis of FTOC initiated with retrovirally
transduced CD34+ thymic progenitors. (A) Dot plots show eGFP vs. CD4 and eGFP vs. CD3 staining gated on live human cells of Nef transduced
cultures, as indicated. Quadrants were set to include 99% of non-transduced cells stained with isotypic controls in lower left quadrant. Numbers
in plots indicate mean fluorescent intensity for the marker on the Y-axis (CD4 or CD3) for all eGFP- cells (upper and lower left quadrants) or all
eGFP+ cells (upper and lower right quadrants) are indicated. (B) T-cell generation ratio calculated from Nef transduced cultures, as indicated. Bars
represent averages of at least 3 independent experiments, error bars indicate standard deviation. Wild-type Nef proteins are shown in dark grey,
VGF-AAA mutants in red. Difference compared to control eGFP (white bar) was tested with Mann–Whitney U test, **p < 0.005, ***p < 0.0005.
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for reduced thymic output in the presence of Nef [25].
To investigate this further, we used HIV-1 subtype
B Nef single point mutants known to be important
for PAK2 binding while not affecting other known
Nef activities. These proteins are mutated in the most
C-terminal phenylalanine residues F191 and F195 forHIV-1 NA7 and SF2 strains respectively, which are
important residues of the HIV-1 Nef PAK2 activating
structural motif (PASM) [20,36,41]. As described be-
fore [35], the NA7 F191H mutant has a reduced
affinity for PAK2 binding, while the NA7 F191R mu-
tant does not bind PAK2 at detectable levels. Simi-
larly, F195 in SF2 Nef was described to be important
Figure 3 SF2 Nef proteins mutated in F195 show reduced PAK2 binding. In vitro kinase assay of AU1-tag immunoprecipitated Nef from cells
transfected with SF2 Nef, constitutive active CDC42, and HA-tagged PAK2, as indicated. Upper panel shows Nef co-immunoprecipitated PAK2
activity, lower panel anti-AU1 staining of cell lysates on Western blot (numbers indicate densitometric quantification).
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tagged SF2 Nef proteins (wild-type, F195I and F195A)
differed in binding capacity for PAK2, they were
transfected in 293 T cells to measure activated PAK2
binding as described before [43,44]. While in this
setting residual binding of PAK2 to SF2 Nef F195I
was detected, binding to SF2 Nef F195A was un-
detectable (Figure 3). When assayed for their effect
on T-cell development, reduced PAK2 binding did
not affect the CD3 or CD4 cell surface stainingFigure 4 Reduction of thymic output by HIV-1 Nef is affected by PAK
transduced CD34+ thymic progenitors. (A) Dot plots show eGFP vs. CD4 an
cultures, as indicated. Quadrants were set to include 99% of cells stained w
plots indicate mean fluorescent intensity for the marker on the Y-axis (CD4
eGFP+ cells (upper and lower right quadrants) are indicated. (B) T-cell gene
represent averages of at least 3 independent experiments, error bars indica
mutants showing reduced PAK2 binding in blue, mutants showing no dete
(white bar) was tested with Mann–Whitney U test, **p < 0.005, ***p < 0.00profiles (Figure 4A) but did diminish the effect on
T-cell development (Figure 4B) in comparison to
wild-type Nef. However, while NA7 F191R did not
affect T-cell generation at all, SF2 F195A was still
partially active (TGR 0.7) despite the fact that no de-
tectable PAK2 activity was bound (Figure 3). This
suggests that in the case of SF2 either a minute but
undetectable PAK2 activity bound to Nef is sufficient
to affect T-cell development, or that other Nef func-
tions contribute to reduced thymic output.2 binding. Flow cytometric analysis of FTOC initiated with retrovirally
d eGFP vs. CD3 staining gated on live human cells of Nef transduced
ith isotypic controls and eGFP cells in lower left quadrant. Numbers in
or CD3) for all eGFP- cells (upper and lower left quadrants) or all
ration ratio calculated from Nef transduced cultures, as indicated. Bars
te standard deviation. Wild-type Nef proteins are shown in dark grey,
ctable PAK2 binding in red. Difference compared to control eGFP
05.
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hamper T-cell development
Since PAK2 interaction with HIV-1 Nefs seems to play
an important role in reduced thymic output, we investi-
gated whether this mechanism is conserved in other len-
tiviral Nef proteins. First, we analyzed the effect of
mutations in prolines P104 and P107 of the polyproline
stretch (PxxP) of SIVmac239 Nef. The mutation of P104
was described to marginally affect PAK2 binding while
P107 was shown to be essential for PAK2 binding [45].
Surprisingly, we found that P107A and the P104A/
P107A double mutant (PxxA and AxxA) could still bind
PAK2 albeit with strongly reduced efficacy (Figure 5A).
We therefore sought other mutants that were selectivelyFigure 5 PAK2 binding of mutant Nef proteins and positional homolo
AU1-tag immunoprecipitated Nef from cells transfected with Nef, constitut
shows Nef co-immunoprecipitated PAK2 activity (figures indicate densitom
cell lysates on Western blot. (B) Alignment of SIVmac239 Nef to a consensu
sequences previously described [36]. Arrows denote SIVmac239 Nef amino
HIV-1 subtype B Nef 85, 89, 188 and 191.defective for PAK2 binding. As mentioned above, we
previously described a PASM in HIV-1 Nef comprised of
amino acids L85, H89, R188 and F191 [36,46]. When we
aligned SIVmac239 protein sequence with a consensus
subtype B Nef sequence [36], SIVmac239 Nef residues
I117, H121, T218 and Y221 were revealed as potential
candidates involved in the binding of PAK2 due to their
positional homology to PASM residues of HIV Nef
(Figure 5B). To determine whether the four candidate
SIV Nef amino acids are indeed involved in PAK2 bind-
ing, we mutated each one to three different substitutions
and measured PAK2 binding. While substitution at all
positions could reduce PAK2 binding (Additional file 1:
Figure S1), our results showed that the H121R andgs of PAK2 activating structural motif. (A) In vitro kinase assay of
ive active CDC42, and HA-tagged PAK2, as indicated. Upper panel
etric quantification), lower panel anti-HA and anti-AU1 staining of
s HIV-1 subtype B Nef sequence derived from a database of 1643
acid residues 117, 121, 218 and 221 which are positional homologs to
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reduced in PAK2 binding. These identified residues
therefore constitute the PASM of SIVmac, homologous
to that of HIV-1 Nef. We also generated a double
mutant that was not able to bind active PAK2 at all
(Figure 5A). The H121R, Y221R single and double
mutants were capable of downregulating the expression
of cell surface CD4, CD3, CD28 and to a lesser extent
MHC-I to similar levels as SIVmac239 Nef in cell
lines and infected human peripheral mononuclear cells
(Additional file 1: Figure S2) and thymocytes (Figure 6A).
In addition, the mutations of H121R/Y221R did not
affect downregulation of MCH class II and upregulation
of invariant chain Ii (Additional file 1: Figure S2D), nor
hyperactivation of NFAT (data not shown) by Nef. By
contrast, downregulation of CXCR4 was compromised
(Table 2).
We found that individual or combined mutations in
the PxxP motif or in residues H121 and Y221 of the
SIVmac239 disrupted PAK2 interaction, but had little if
any effect on reduction of thymic output (Figure 6B).
This shows that PAK2 binding is not essential, or thatFigure 6 PAK2 binding is not essential and downregulation of CD3 is
cytometric analysis of FTOC initiated with retrovirally transduced CD34+ thy
staining gated on live human cells of Nef transduced cultures, as indicated
with isotypic controls in lower left quadrant. Numbers in plots indicate me
all eGFP- cells (upper and lower left quadrants) or all eGFP+ cells (upper an
calculated from Nef transduced cultures, as indicated. Bars represent averag
deviation. Nef proteins that bind PAK2 and downregulate CD3 are shown i
with no detectable PAK2 binding in red, mutants showing no detectable P
to control eGFP (white bar) was tested with Mann–Whitney U test, *p < 0.0residual but undetectable PAK2 binding is sufficient, for
the reduction of thymic output by SIVmac239 Nef. In
contrast to HIV-1 Nef, SIVmac Nef downregulates CD3
in CD4+ lymphocytes [28]. Since CD3 is important for
TCR signal transduction and T-cell development critic-
ally depends on TCR signaling [47], we hypothesized
that this function may explain why loss of PAK2 binding
did impair the effect of SIVmac239 Nef on thymic
output. To examine this we utilized two previously
described SIVmac Nef deletion mutants: nefΔ153 and
nefΔ183 [48]. The NefΔ153 protein does not downregulate
CD4, CD28 and MHC-I or enhance viral infectivity and
replication but still reduces CD3 surface expression. By
contrast, the nefΔ183 allele has also lost the latter
function due to an additional deletion of 10 amino acids.
These phenotypical characteristics were confirmed
in transduced thymocytes that developed in FTOC
(Figure 6A) and in CD4+ PBLs (Table 2). As expected,
both proteins were unable to bind PAK2 (Figure 5).
However, NefΔ153 still reduced thymic output, whereas
NefΔ183 was inactive (Figure 6B). Thus CD3 downregula-
tion by SIVmac Nef is sufficient to block T-cellsufficient to hamper T-cell development by SIV Nef. Flow
mic progenitors. (A) Dot plots show eGFP vs. CD4 and eGFP vs. CD3
. Quadrants were set to include 99% of non-transduced cells stained
an fluorescent intensity for the marker on the Y-axis (CD4 or CD3) for
d lower right quadrants) are indicated. (B) T-cell generation ratio
es of at least 3 independent experiments, error bars indicate standard
n dark grey, mutants showing reduced PAK2 binding in blue, mutants
AK2 binding nor CD3 downregulation in black. Difference compared
5, **p < 0.005, ***p < 0.0005.
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exclude other SIVmac239 Nef functions to contribute to
this effect. However, no SIVmac mutant Nef protein was
available that selectively lost PAK2 and CD3 downregu-
lating properties.
Finally, we also tested the Nef allele of SIVblu infect-
ing blue monkeys (Cercopithecus mitis) and a mutant
thereof (RR-AA) containing amino acid changes R129A
and R130A. In comparison to the wild-type protein, the
SIVblu RR-AA mutant lost its ability to downregulate
CD3 in thymocytes and PBLs (Figure 6A and Table 2)
and bind PAK2 (Figure 5A). Nonetheless, the protein
still impaired T-cell generation, albeit to a lower extent
when compared to SIVblu wild-type Nef (TGR 0.5 and
0.2 respectively, Figure 6B). As CXCR4 signaling is im-
portant for T-cell development [49,50], the downregula-
tion of CXCR4, conserved in SIVblu RR-AA possibly
contributes to this residual effect.
Discussion
We show here that expression of highly diverse primate
lentiviral Nef proteins in human T-cell progenitors re-
duces their development into T cells. Primate lentiviral
Nefs may impair thymic output by at least three mecha-
nisms including PAK2 interaction and downregulation
of CD3 or CXCR4. The effect of HIV-1 Nefs on T-cell
development is mainly dependent on PAK2 interaction
since they generally lack the CD3 down-modulation
function and have only weak effects on CXCR4. In con-
trast, SIV Nefs lacking PAK2 interaction maintain the
ability to reduce thymic output, either by downregula-
tion of CD3 or CXCR4 .
Reduced thymic output most likely contributes to the
failure to compensate for increased destruction of CD4+
T cells in lymphoid tissues in HIV-1 infected patients,
ultimately resulting in AIDS [51]. Thymic progenitors
have been shown to be infected at significant rates in pa-
tients [3,4,52]. In these cells, expression of Nef may
block the generation of differentiated T cells. Also in
HIV-2 infected patients, reduction in recent thymic emi-
grants was seen in younger patients (<45 years of age),
as measured by signal joint/beta T-cell receptor excision
circle levels in circulating lymphocytes. T-cell develop-
ment is process requiring differentiation of CD34+
thymic precursor cells into successive stage of thymo-
cytes undergoing selection to express suitable TCRs
[47,53]. In this process, interaction of developing thymo-
cytes with the environment through cell surface recep-
tors while migrating through the organ is of pivotal
importance. It is therefore conceivable that a viral pro-
tein that affects migration (through PAK2 binding) and
expression of receptors important for T-cell develop-
ment (CD3 and CXCR4) would be capable of disrupting
T-cell generation. Remarkably, all SIV Nef proteinstested in this study, including those from SIV that do
not provoke disease in their natural host, were able to
hamper human T-cell development, indicating that
required interactions with host proteins are conserved
across species. While downregulation of CD3 will impair
thymic output, reduced immune activation in the
periphery might outweigh this so that SIV infection by
CD3 downregulating strains is marked by a relative
preservation of peripheral CD4+ T-cell counts in the
natural hosts. Primate lentiviruses, however, differ in Nef
function. While most Nef proteins downregulate CD4
and MHC-I, and bind to kinases such as PAK2, HIV-1
and its simian precursor SIVcpz are peculiar in that the
encoded Nef proteins have lost the ability to downregu-
late CD3 [16]. This is in contrast to Nefs encoded by
HIV-2 and its closest simian counterpart SIVsmm/SIV-
mac. In addition, the latter also downregulate CXCR4
more potently than HIV-1/SIVcpz Nef [34]. Our previ-
ous work with HIV-1 subtype B Nef showed that down-
regulation of CD4, CD8β or MHC-I did not correlate
with the reduced thymic output by Nef [25]. However,
we showed several motifs involved in PAK2 binding
(acidic cluster, polyproline domain, R106) to be import-
ant for deregulating T-cell development. We recently
identified a VGF domain, linking the acidic cluster and
the polyproline motif, important for many Nef functions
including PAK2 binding [29]. Here we show that this
VGF motif is also essential for the effect of HIV-1 Nef
on thymic output. To investigate the role of PAK2 more
specifically, we used point mutants of the C-terminal
phenylalanine known to affect PAK2-Nef binding, i.e.
F191 (NA7)/F195 (SF2). The NA7 F191R mutant Nef
lost its effect on thymic output completely, demonstrat-
ing that at least in some HIV-1 Nef alleles, PAK2 bind-
ing is crucial for reducing thymic output. However,
F195A mutant of SF2 Nef maintained some activity in
reducing thymic output (TGR 0.7 compared to TRG 0.1
for wild-type SF2), despite the complete loss of detect-
able PAK2 binding.
SIVmac Nefs, which in contrast to HIV-1 and SIVcpz
Nef, downregulate CD3 and more potently downregulate
CXCR4, also bind PAK2 and reduced thymic output very
efficiently (TGR 0.3 or below). To investigate the im-
portance of PAK2 binding by these proteins we used
previously described and newly developed mutants. The
SIVmac Nef double mutant P104A/P107A still bound
detectable PAK2 activity, which could explain the ob-
served effect on T-cell development (TGR 0.2). To rule
this out, we developed mutant proteins based on the
positional homology with the HIV-1 PAK2 activating
structural motif (PASM) we described before [36]. In
SIVmac Nef, 4 residues were identified that critically
contribute to PAK2 binding. Similar to HIV-1 Nef,
SIVmac thus forms a PASM that points to the relevance
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us to create selective mutants. Nef-PAK2 binding was
strongly reduced in the H121R and Y221R single
mutants, and undetectable for the double mutant. This
double mutant still significantly reduced thymic output
(TGR 0.5) compared to eGFP expressing control cul-
tures (TGR 1.4), albeit with reduced potency when
compared to wild-type SIVmac (TGR 0.1). Thus, differ-
ent from what we observed with HIV-1 NA7 Nef, SIV-
mac239 Nef proteins mutated in residues relevant for
PAK2 binding (P104, P107, H121 and Y221) still reduce
thymic output, albeit at slightly reduced levels (TGR
from 0.2 to 0.6) compared to wild-type SIVmac239 Nef
(TGR 0.1). Compared to wild-type, these PAK2-binding
Nef mutants were attenuated in downregulation of
CXCR4 but fully active as wild-type to downregulate
CD3. Here we demonstrate that an internally deleted
SIVmac Nef protein that lost all of its known functions
except downregulation of CD3 from the cell surface
(nefΔ153) [48] can block T-cell development (TGR 0.1).
Downregulation by SIVmac239 Nef of CD3 is thus suffi-
cient to reduce thymic output, and might compensate
for defects in PAK2 binding and CXCR4 downregulation
in the mutants discussed above.
Downregulation of CXCR4 will most likely contribute
to impaired T-cell development, given the essential role
of SDF1α/CXCR4 signaling in this process [49,50]. This
is underscored by the residual effect on thymic output of
the SIVblu RR-AA Nef mutant, that lost the capacity to
bind PAK2 and downregulate CD3 but retained CXCR4
downregulation, compared to the wild-type protein.
Possibly, the effects of Nef on thymic output might also
involve the re-localization of the tyrosine kinase Lck
away from plasma membrane to the trans-golgi network
[54]. Since Nef-mediated retargeting of Lck alters its sig-
nal transduction properties [55,56] and association of
this tyrosine kinase to the CD4/CD8 co-receptor is im-
portant for thymocyte selection [57], Nef may disrupt
signaling events essential for thymocyte generation via
this mechanism. In support of such a scenario, at least
in transgenic mice, overexpression of constitutive active
Lck abrogated the effects of Nef on T-cell development
[58]. Testing the relative contribution of CXCR4 down-
regulation or of Lck re-localization to the reduction of
thymic output by Nef will require the identification of
mutants or variants of the viral protein that are select-
ively defective for these activities.
Conclusion
In conclusion, we showed that reduced thymic output is
a conserved feature of primate lentiviral Nef proteins.
For HIV-1 Nef, active PAK2 binding is crucial to this
effect, while the CD3 downregulation e.g. by HIV-2 Nef
and other SIV Nef proteins is sufficient to provoke ablock in T-cell development. The latter proteins will in
addition downregulate CXCR4, what might contribute to
their effect on T-cell development. Thus depending on
the context, multiple Nef functions contribute to the re-
duction of thymic output, what appears to be a well con-
served and likely relevant effect of primate lentivirus Nef
proteins. Infection of the thymus, leading to expression
of Nef in developing thymocytes, may contribute to this
decline. Further mechanistic exploration of Nef function
in developing and differentiated T cells is needed to elu-
cidate the importance of Nef-mediated reduced thymic
output for the pathogenesis of AIDS.
Methods
Viruses, vectors and molecular clones
HIV-1 group M and group O isolates were obtained
from the AIDS Research and Reference Reagent Pro-
gram, while the HIV-2 strains were previously isolated
from patients attending the AIDS clinic at the Institute
of Tropical Medicine in Antwerp, Belgium, with the
approval of the ethical committee after written informed
consent. The nef genes from these isolates were available
in the LZRS-IRES-eGFP retroviral vector constructed
before [29]. Similarly, nef sequences from SIVcpz
(GAB2), SIVmac (239), SIVsmm, SIVgor, SIVblu and de-
rived mutants [33,39,40] were amplified and cloned into
the same vector. In some cases tagged proteins and new
mutants were created by overlap extension PCR or
site-directed mutagenesis (primers in Additional file 1:
Table S1). Double mutant SIVmac 239 H121R/Y221R
was constructed starting from cloned single mutant PCR
amplicons, taking advantage of the PsiI restriction site
that is internal relative to the 121 and 221 residues.
Single and double mutant nef were further subcloned by
introducing the BglII/NdeI SIV nef mutated fragments
into a construct comprised of a ClaI/EcoRI fragment
from SIVmac239 FL SPX (kindly provided by Dr. R.
Desrosiers, Harvard Medical School, Boston). These
were used to clone by PCR the mutant nef sequences in
expression vectors and retroviral vector plasmids,
and in replication competent HIV-1 reporter virus
(see Additional file 1: Methods). For in vitro kinase as-
says (IVKA), nef sequences were amplified with primers
containing an AU1 tag sequence for C-terminal tagging
and cloned in the pCG expression plasmid as described
before [39]. The integrity of the constructs and the nef
genes was confirmed by Sanger sequencing, protein
expression was evident from Western blot and/or bio-
logical activity.
Retroviral gene transfer
The Phoenix-Amphotropic packaging cell line was trans-
fected with LZRS retroviral vector plasmids to produce
nef-IRES-eGFP bicistronic mRNA encoding retroviral
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transduction of CD34+ thymus cells was performed as de-
scribed before [24,25]. Briefly, CD34+ cells were seeded on
RetroNectin (Takara Biomedicals, Otsu Shiga, Japan)
coated culture plates with half of the medium volume re-
placed by retroviral supernatants, supplemented with SCF
(10 ng/mL) and IL-7 (10 ng/mL). Transduced CD34+ cells
were used after 24 hours for fetal thymus organ cultures
(FTOC). The excess of transduced progenitor cells, which
were not used in FTOC, were kept in culture for 72 hours,
to determine the transduction efficiency that varied be-
tween 10% and 20%. Child thymus tissue, removed during
cardiac surgery, was obtained and used following the
guidelines of the Medical Ethical Commission of Ghent
University Hospital. Written informed consent was pro-
vided according to the Declaration of Helsinki.
Fetal thymic organ cultures (FTOC) and flow cytometry
Isolation of thymic lobes from fetal nonobese diabetic
(NOD)-SCID mice and subsequent murine FTOC were
performed and analyzed as described previously [25,59].
Mice were treated and used in agreement with the
guidelines of the local ethical committee. To asses
thymic depletion due to Nef expression we calculated
the thymocyte generation ratio (TGR), which is defined
by the ratio of the percentage of eGFP+ thymocytes har-
vested to the percentage of CD34+ eGFP+ progenitors
that were put in FTOC [25,59]. To asses cell surface
modulation by the different Nef proteins, we isolated
CD4+ cells (PBLs) from buffy coat peripheral blood
mononuclear cells (normal blood donors, Red Cross,
Ghent, Belgium) by negative selection using paramag-
netic beads (MACS; Miltenyi Biotec, Bergish Gladbach,
Germany). After isolation, the cells were cultured for
3 days in RPMI medium supplemented with 2 mM
L-glutamin, 10% heat-inactivated fetal calf serum, phyto-
hemagglutinin (1 μg/mL; Thermo Fisher Scientific,
Waltham, USA), 20 ng/mL IL-2 (Peprotech, Rocky Hill,
USA), 100 U/mL penicillin, and 100 g/mL streptomycin.
Thereafter, PBLs were transduced with retroviral vectors
on Retronectin RetroNectin (Takara Biomedicals, Otsu
Shiga, Japan) coated culture plates with half of the
medium volume replaced by retroviral supernatants,
supplemented with IL-2 to keep final cytokine concen-
trations constant. After another 2 days of culture,
cells were harvested and stained for flow cytometry.
Antibodies used were directly labeled mouse monoclo-
nals anti-CD1 phycoerythrin [PE] and anti-HLA-A, -B,-
C-PE (Becton Dickinson, Erembodegem, Belgium),
anti-CD8β-PE (Coulter, Miami, FL) anti-CD3 allophyco-
cyanin [APC], anti-CD4-APC and anti-CXCR4-PE-Cy7
(Miltenyi Biotec, Bergisch Gladbach, Germany), flow cyt-
ometers used were FACSCalibur (Becton Dickinson) and
MACSQuant (Miltenyi Biotec).Western blotting and in vitro kinase assay (IVKA)
Western blot and IVKA was performed as described be-
fore [43]. Briefly, HA-tagged PAK2, dominant-active
Cdc42V12 and AU1-tagged Nef were transfected into
293 T cells. Lysates of transfected cells were in part
subjected to immunoblot to quantify total amount of
tagged proteins, and in part used for anti-AU1 Babco,
Richmond, CA) immunoprecipitation using protein
G-Sepharose beads. Immunoprecipitate was incubated to
detect autophosphorylation activity of PAK2 in the pres-
ence of 32P-ATP by autoradiography of SDS-PAGE.
Statistics
Analyses were performed using the GraphPad Prism ver-
sion 5.00 statistical software (GraphPad Software Inc.,
La Jolla, CA, USA), non-parametric tests used were
Mann–Whitney U test and Kruskal-Wallis with Dunn’s
correction for multiple testing.
Additional file
Additional file 1: Supplementary Methods. Table S1. Primers used
to generate mutant and tagged Nef protein expression constructs.
Figure S1. SIVmac239 Nef displays a PAK2-activating structural domain
surface and Figure S2. Cell surface marker modulation by SIVmac239
mutated in PAK2-59 activating structural domain surface.
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